Rabies kills virtually every person who develops symptoms, yet a small number of patients have defied that near-absolute fatality rate. Across the medical literature, about 34 well-documented survivors exist, most left with severe neurological damage. Their cases raise a difficult question: does survival after symptomatic rabies represent a replicable medical achievement, or a statistical anomaly that tells us more about diagnosis than treatment?
A Virus With Almost No Equal
No other documented virus carries a 100% fatality rate in humans, according to virology overviews. Rabies comes close. The World Health Organization describes the disease as “virtually 100% fatal” once clinical signs appear and classifies it as a serious public health problem in over 150 countries and territories, mainly in Asia and Africa. Dog-mediated transmission accounts for up to 99% of human cases globally, according to the WHO’s rabies fact sheet. The incubation period typically runs two to three months but can range from one week to one year, a window that makes post-exposure prophylaxis, or PEP, highly effective if administered before symptoms begin.
In the United States, human rabies deaths are rare but still occur, often after seemingly minor bat encounters when patients do not seek PEP in time. A CDC surveillance report documented recent fatal infections in Minnesota and California that followed exactly this pattern. The disease remains preventable through prompt vaccination and immune globulin, yet once symptoms set in, no evidence-based curative treatment exists. The CDC’s travel medicine guidance on rabies management emphasizes that clinical cases are typically handled with supportive or palliative care rather than any proven antiviral regimen.
Jeanna Giese and the Milwaukee Protocol
The most famous rabies survivor is Jeanna Giese, who recovered from clinical rabies in Wisconsin in 2004 after a bat bit down hard on her finger during church. She received no PEP. By the time she reached the hospital with neurological symptoms (unsteady gait, slurred speech, and confusion), her doctors faced a disease with no established cure. A team led by pediatric infectious disease specialist Rodney Willoughby placed her in an induced coma and administered a combination of intensive care and adjunct drugs, including ketamine, midazolam, and antiviral therapy, a strategy later named the Milwaukee Protocol.
Diagnostic testing sent to the CDC, including serum, cerebrospinal fluid, skin, and saliva samples, confirmed the diagnosis: rising rabies antibody titers in both serum and CSF were inconsistent with vaccination, ruling out a false positive. The case was published in the New England Journal of Medicine by Willoughby and colleagues, including CDC rabies expert Charles Rupprecht, and quickly circulated as the first documented survival of unvaccinated, symptomatic human rabies without prior PEP.
Giese’s recovery drew global attention. She later described being placed in a coma, waking to months of rehabilitation, and now working with children in Wisconsin, living with subtle but manageable neurological after-effects. The Milwaukee Protocol rapidly gained recognition worldwide as a possible means to save unvaccinated rabies patients. A third unvaccinated U.S. clinical rabies recovery followed in California in 2011, documented in a separate CDC case report that again attracted media attention.
Yet a pattern emerged in these U.S. survivors that complicates the narrative: none had detectable virus, antigen, or RNA in brain tissue or saliva. Diagnosis rested entirely on a compatible clinical syndrome plus rabies-specific antibodies in serum or CSF. That has led some researchers to suggest that these patients might have mounted unusually rapid immune responses that limited viral spread before it fully invaded the central nervous system. In that scenario, survival might reflect partial infection controlled by the host, rather than a universally applicable therapeutic breakthrough.
Dozens of Failures Cast Doubt
The optimism around the Milwaukee Protocol has not held up under scrutiny. A peer-reviewed analysis in Clinical Infectious Diseases, examining the protocol’s track record across multiple countries, found that it has not demonstrated efficacy beyond the original Giese case. At least dozens of attempts to replicate the approach have failed, with patients dying despite aggressive coma induction, antiviral drugs, and neuroprotective strategies. The authors argued that critical care itself (airway protection, hemodynamic support, and careful management of complications) may be the only beneficial component of treatment for symptomatic patients.
A separate critique in Virology Journal reached a similar conclusion, stating that the Milwaukee Protocol is not valid as a general treatment approach for human rabies and should not be promoted as a standard of care. In many reported attempts, the protocol was initiated late in the disease course, in resource-limited settings, or without full adherence to the original regimen, complicating interpretation. But even in better-resourced hospitals, survival has been the rare exception rather than the rule.
This distinction between supportive care and experimental protocols matters. Researchers writing in the Southern African Journal of Infectious Diseases have explicitly separated cases where patients survived through basic supportive care from those treated under experimental regimens like the Milwaukee Protocol. The difference suggests that rare survivors may owe their outcomes less to any specific drug combination and more to aggressive management in well-equipped intensive care units, combined with host factors such as viral strain, inoculum size, and individual immune response. If that reading is correct, the protocol’s fame may have misdirected research attention and scarce resources for nearly two decades.
Survivors Around the World
Survival cases are not limited to the United States. A detailed case report from South Africa documented a teenage boy who developed furious rabies after a dog bite yet ultimately survived. He received intensive supportive care, including ventilation and management of autonomic instability, but not a full Milwaukee-style coma regimen. Clinicians detected rabies virus–specific antibodies and compatible clinical signs, and the patient gradually improved over months, though he was left with significant neurological impairment.
Elsewhere, case series from India have described multiple patients who lived through clinical rabies. In at least one of these, polymerase chain reaction (PCR) testing confirmed rabies virus RNA, strengthening the argument that true post-symptomatic survival is possible, albeit extraordinarily rare. These international cases share a grim thread: survivors almost universally suffer severe neurological sequelae. Paralysis, cognitive deficits, behavioral changes, and lasting disability are common outcomes, often requiring long-term rehabilitation and caregiving support.
A 2025 review in the journal Travel Medicine and Infectious Disease synthesized global reports and confirmed that only a small number of rabies survivors have been described in the medical literature, and most endured severe neurological deficits. The authors stressed that these cases should not be interpreted as evidence that rabies is becoming less lethal, but rather as rare outliers that highlight the need for better understanding of host-pathogen interactions.
Statistical Outliers or Therapeutic Clues?
How should clinicians and public health officials interpret these survivors? One view holds that they are statistical outliers: in a disease with hundreds of thousands of deaths over decades, a few apparent recoveries might be expected due to misdiagnosis, atypical immune responses, or partial infections that never fully reached the brain. In this framing, the core message remains unchanged: rabies is essentially fatal once symptoms appear, and prevention through vaccination after exposure is the only reliable safeguard.
Another view is more optimistic. If some patients can clear or contain rabies after symptom onset, studying them could reveal protective immune mechanisms or genetic factors that might be leveraged therapeutically. For example, unusually rapid production of neutralizing antibodies in the central nervous system, or specific patterns of innate immune activation, might correlate with survival. Identifying such signatures could guide adjunctive therapies or risk stratification in future clinical trials.
For now, however, there is no validated protocol that reproducibly turns symptomatic rabies into a survivable disease. The scattered successes do not justify withholding PEP, delaying palliative discussions, or offering families false hope. Instead, they underscore two practical imperatives: ensuring that high-quality intensive care is available where possible, and rigorously documenting every suspected survivor with virologic, immunologic, and long-term follow-up data.
The Uncomfortable Bottom Line
Rabies remains, in functional terms, one of the deadliest infections known to medicine. A handful of survivors, Jeanna Giese among them, demonstrate that the virus’s fatality is not mathematically absolute. Yet their stories do not change the public health calculus. The disease is overwhelmingly preventable through timely PEP, and almost uniformly lethal without it.
For clinicians, the lesson is to treat every potential exposure with urgency, especially in regions where dog-mediated rabies is endemic and access to vaccines is uneven. For researchers, the charge is to learn what they can from rare survivors without overselling unproven protocols. And for the public, the message is stark but empowering: avoid contact with potentially rabid animals, seek prompt medical care after any suspicious bite or scratch, and recognize that in the case of rabies, prevention is still the only reliable cure.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
